



---

**Fiscal Year (FY) 2022 Inpatient Prospective Payment System (IPPS) New  
Technology Add-on Payment (NTAP) Virtual Town Hall Meeting**

*Wednesday, December 16, 2020*

**\*\*\*Please click this URL to join.\*\*\***

<https://cms.zoomgov.com/j/1602047237?pwd=NzlxS1hCeHl4TmpZUDRML2dxdzNOQT09>

*Or join by phone:*

*Dial: US: +1 669 254 5252 or +1 646 828 7666*

*Webinar ID: 160 204 7237*

*Passcode: 949958*

Each presentation is 15 minutes long, including any time for questions and answers. Please note that while we will do our best to adhere to this schedule, times are subject to change.

**FY 2022 NTAP Town Hall Day 2 Agenda (all times shown in EST)**

8:30-9:00am: **Meeting Registration:** Registration for attendees not presenting at the meeting is not required. However, attendees that would like to receive emailed notifications in the event of CMS technical issues during the virtual town hall meeting may use the following registration link to provide contact information:

[https://cms.zoomgov.com/webinar/register/WN\\_Nn4SVVp4R-mICfgf2TfN-w](https://cms.zoomgov.com/webinar/register/WN_Nn4SVVp4R-mICfgf2TfN-w)

9:00-9:15am: **Welcome**

9:15-9:30am: **Lisocabtagene maraleucel** - an autologous chimeric antigen receptor (CAR) T-cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.

**Presenters: Matthew Lunning DO, FACP**

Associate Professor

Fred & Pamela Buffett Cancer Center

University of Nebraska Medical Center

**Mecide Gharibo, MD**

US Medical Affairs Executive Director

Lymphoma/CLL and CAR T Lead

Bristol Myers Squibb

- 9:30-9:45am: **Ciltacabtagene autoleucel** - an autologous chimeric antigen receptor (CAR) T-cell immunotherapy for the treatment of relapsed or refractory multiple myeloma.  
**Presenter: Vadim Romanov, MD, MPhil, FFPM**  
Head of CAR Ts  
US Medical Affairs  
Janssen
- 9:45-10:00am: **Idecabtagene vicleucel** - an autologous chimeric antigen receptor (CAR) T-cell immunotherapy for the treatment of relapsed or refractory multiple myeloma.  
**Presenters: Nina Shah, MD**  
Associate Professor Clinical Medicine  
Hematology and Oncology  
University of California, San Francisco Health  
  
**Amit Agarwal, MD, PhD**  
Global Disease Lead, Multiple Myeloma  
Bristol Myers Squibb
- 10:00-10:15am: **TECARTUS® (brexucabtagene autoleucel)** - a CD19-directed, genetically modified chimeric antigen receptor (CAR) T-cell immunotherapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.  
**Presenter: Bijal Shah, MD, MS**  
Section Leader, MCL and Acute Lymphoblastic Leukemia  
Associate Member, Malignant Hematology  
Moffitt Cancer Center
- 10:15-10:30am **Amivantamab** - a bispecific monoclonal antibody for the treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR exon20 insertion mutations.  
**Presenter: Parthiv Mahadevia, MD**  
Senior Global Medical Affairs Leader  
Oncology Medical Affairs  
Janssen
- 10:30-10:45am: **Break**

- 10:45-11:00am: **ZEPZELCA™** - a drug for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.  
**Presenter: Mary J. Fidler, MD**  
Medical Oncology, Rush University Medical Group  
Associate Professor, Department of Internal Medicine  
Division of Hematology, Oncology and Cell Therapy  
Rush Medical College
- 11:00-11:15am: **Trilaciclib** - a first-in-class myelopreservation therapy that has the potential to mitigate chemotherapy-induced myelosuppression (CIM).  
**Presenter: Marc Chioda, PharmD**  
Vice President, Medical Affairs  
GI Therapeutics
- 11:15-11:30am: **Steripath® Micro™ Blood Collection System** - a proprietary and patent-protected Initial Specimen Diversion Device® (ISDD®) for blood culture collection and contamination prevention.  
**Presenter: Greg Bullington**  
CEO & Founder  
Magnolia Medical Technologies, Inc.
- 11:30-11:45am: **Pure-Vu System** – a system comprised of a workstation and colonic oversleeve that connects to currently marketed colonoscopes to provide high intensity intra-procedural cleansing of the colon during colonoscopy.  
**Presenter: TBD**
- 11:45-12:00pm: **Wrap-up and Conclusion for FY 2022 NTAP Town Hall**

**Public Comments on Substantial Clinical Improvement:** Comments for consideration in the IPPS proposed rule related to the substantial improvement criterion for NTAP (including comments on the FY 2022 applications and on the town hall presentations) **must be sent to CMS via email to [newtech@cms.hhs.gov](mailto:newtech@cms.hhs.gov). All comments must be received by 5:00 pm EST on Monday, December 28, 2020.**